The management of CML progressed extensively after imatinib was first described in 1996 as a tyrosine kinase inhibitor (TKI) specific to BCR–ABL1 [12, 13]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.